期刊
NEUROLOGY
卷 72, 期 11, 页码 1008-1015出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/01.wnl.0000344417.42972.54
关键词
-
资金
- Bayer
- Biogen Idec/Elan
- Sanofi-Aventis
- Schering
- Serono
- Teva Pharmaceuticals
In this essay, we draw attention to some recent downsides and surprises of multiple sclerosis (MS) therapeutics. These include experiences with recent head-to-head trials of interferon-beta and glatiramer acetate, dose escalation trials, frustrating efforts with progressive MS trials, failures of smart concepts and designer therapies, and harsh lessons from newly observed adverse reactions. Neurology (R) 2009; 72: 1008-1015
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据